[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1990002566A1 - Proteine de fusion de paramyxovirus, procede de production utilisant un vecteur d'expression de baculovirus de recombinaison, vaccin comprenant ladite proteine et son utilisation - Google Patents

Proteine de fusion de paramyxovirus, procede de production utilisant un vecteur d'expression de baculovirus de recombinaison, vaccin comprenant ladite proteine et son utilisation Download PDF

Info

Publication number
WO1990002566A1
WO1990002566A1 PCT/US1989/003740 US8903740W WO9002566A1 WO 1990002566 A1 WO1990002566 A1 WO 1990002566A1 US 8903740 W US8903740 W US 8903740W WO 9002566 A1 WO9002566 A1 WO 9002566A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
vaccine
paramyxoviral
fusion
infection
Prior art date
Application number
PCT/US1989/003740
Other languages
English (en)
Inventor
Richard W. Compans
Ranjit Ray
Original Assignee
Molecular Engineering Associates, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Engineering Associates, Inc. filed Critical Molecular Engineering Associates, Inc.
Publication of WO1990002566A1 publication Critical patent/WO1990002566A1/fr
Priority to DK91375A priority Critical patent/DK37591D0/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention relates to the use of recombinant DNA technology for the production of subunit vaccines.
  • the invention relates to protein displaying properties of paramyxoviral fusion protein (F protein) produced using a baculovirus expression vector and to the use of such protein as a vaccine against paramyxovirus infection, particularly infection by human parainfluenza type 3 virus.
  • F protein paramyxoviral fusion protein
  • Parainfluenza viruses are members of the paramyxovirus group which also includes mumps and
  • Newcastle disease viruses Human parainfluenza type 3 (PI3; he adsorption type 1) virus, which is probably the most common among the parainfluenza viruses, causes severe respiratory disease, particularly in children.
  • the hemagglutinin-neuraminidase (HN) and fusion (F) glyocproteins of the paramyxovirus group viruses are known to be responsible for initiation and progress of the infection process. The characterization of these envelope glycoproteins has, been reported, R. Ray et al., J. Infect. Dis., , 15.2, 1219-30 (1985); K. van Wyke Z Coelingh et al. , Virology, 143, 569-82 (1985); A.
  • modified live virus as well as chemically-inactivated virus.
  • modified live virus to effect immunization entails an element of risk, in that the avirulent, but still active virus may revert to its virulent state after administration to the recipient.
  • chemically-inactivated virus there is evidence which tends to show that chemical treatment of the virus destroys some of the important antigenic sites responsible for eliciting a. protective immune response.
  • subunit vaccines have provided an alternative to immunization using modified live virus. Patients immunized with subunit vaccines receive only those proteins which produce the desired immunogenic effect. Therein lies the advantage of subunit vaccines, as the risk of infection is substantially avoided.
  • subunit vaccine were isolated from virus-infected cell lysates, purified by immunoaffinity chromotography using specific monoclonal antibodies and reconstituted into lipid vesicles.
  • Subunit vaccines have also been produced more recently using recombinant DNA technology. According to this approach, proteins capable of eliciting protective antibodies in a host are produced by the molecular cloning and expression of the viral genome
  • F protein paramyxovirus fusion protein
  • the protein of the 6 invention may be formulated into a vaccine for immunization against paramyxoviral infection.
  • the present invention provides a protein displaying the antigenic activity of PI3 virus.
  • This protein exhibits reactivity with specific monoclonal and polyclonal antibodies to the F protein of PI3 virus and has an apparent molecular mass of 70 kilodaltons. Immunization of test animals with this protein elicited antibody which neutralized infectivity and blocked fusion of PI3 infected cells. The protective response to challenge infection of animals immunized with this protein was similar to that previously observed with affinity purified F protein from PI3 virus.
  • FIG. 1 is a representation of the construction of the recombinant baculovirus vector of the invention containing F-gene sequences of PI3 virus (pAcYMl-F) .
  • FIG. 2 shows the results of Southern blot analysis of Bam HI digested genomic DNAs from mock infected Sf8 cells (lane 1), AcNPV infected cells (lane 2) and recombinant baculovirus-infected cells (lane 3) using F-gene specific sequences of PI3 virus as a probe.
  • the arrow on the right indicates the position and size in kilobase pair of the inserted F gene.
  • FIG. 3 shows the results of immune precipitation of 3 5s-methionine labeled proteins from PI3 virus infected LLC-MK2 cells (lanes 1 and 5), recombinant baculovirus infected Sf8 cells (lanes 2 and 6), AcNPV infected Sf8 cells (lanes 3 and 7) and mock infected Sf8 cells (lanes 4 and 8) using monoclonal antibody to the F protein of PI3 virus.
  • FIG. 4 shows the results of surface immunofluorescence analysis of recombinant baculovirus-infected cells (panel A) and AcNPV-infected cells (panel C) using monoclonal antibody to the F protein of PI3 virus.
  • Phase-contrast view of recombinant baculovrius infected cells (panel B) and AcNPV infected cells (panel D) are also shown.
  • the present invention enables production, in an insect host system, of recombinant F protein which closely resembles the naturally-occurring paramyxoviral F protein both i munologically and physically.
  • the insect host cells are infected with a recombinant baculovirus expression vector capable of expressing the exogenous F protein gene within the host.
  • the resultant F protein, or immunologically significant subunits or epitopes thereof is a useful immunogen in a paramyxoviral vaccine.
  • the primary function of the F glycoprotein in the paramyxovirus life cycle is to achieve fusion of internalized virions with intracellular membranes to affect capsid release.
  • the F protein is also involved in the formation of syncytia between infected. cells. 1 :
  • the F protein is found in different viruses of the paramyxovirus group, and recombinant F proteins may be made by the method of the invention which antigenically resemble the F glycoprotein of human parainfluenza virus I, II, III or IV, mumps virus, measles virus, respiratory syncytial virus, animal viruses including Newcastle disease virus, Sendai virus, and other paramyxoviruses which infect different animals such as cattle and birds. It is desirable in the art of preparing recombinant eucaryotic proteins or glycoproteins to express the recombinant protein using a eucaryotic expression system, for example, insect cells.
  • a eucaryotic expression system for example, insect cells.
  • Certain types of insect and other invertebrate host cells have the ability to express an exogenous gene at a high level and in an environment which resembles its normal cellular surroundings.
  • the host cell machinery of a eukaryotic cell is more likely to produce the desired protein in authentic form with respect to antigenic and immunogenic properties, so as to elicit effective immunity to infection.
  • Eucaryotic expression systems are also capable of transporting the finished product to its target cellular location, which in the case of the, F protein is the plasma membrane.
  • F protein is the plasma membrane.
  • the present invention utilizes baculovirus vectors which are able to infect cultured insect cells efficiently.
  • Lytic DNA viruses such as the insect baculoviruses, contain non-essential portions of the viral genome which can be replaced with exogenous DNA while substantially maintaining the viral replication function. Due to the lytic replication cycle of the virus, only transient expression of the exogenous DNA or gene can be achieved using a baculovirus vector.
  • the baculovirus expression vector of the invention is generally prepared by the following series of steps. A fragment of DNA is provided comprising baculoviral genomic DNA containing a viral promoter, a structural gene associated with the viral promoter, and flanking viral sequences. The aforesaid fragment may be enzymatically cleaved directly from baculovirus genomic DNA.
  • the aforesaid fragment is cloned into a bacterial plasmid.
  • a transfer vector Using jji vitro mutagenesis, all or part of the structural gene associated with the viral promoter is deleted from the plasmid, resulting in the formation of a transfer vector.
  • the exogenous gene to be expressed is then inserted into the transfer vector such that the exogenous gene is under control of, and in correct orientation relative to, the promoter.
  • the transfer vector is then cotransfected together with baculovirus genomic DNA into a suitable transfer host, wherein a recombination event can insert the DNA segment comprising the promoter and exogenous gene under its control into a baculoviral genome.
  • a phenotypic trait which characterizes the nuclear polyhedrosis viruses and the granulosis viruses is the formation of occlusion bodies as a part of the viral life cycle.
  • the primary component of occlusion bodies is polyhedrin, a polypeptide having a molecular weight of approximately 30,000.
  • the most extensively characterized baculovirus is the type A nuclear polyhedrosis virus isolated from the caterpillar
  • AcNPV Autographa californica
  • the AcNPV baculovirus is the preferred viral vector in the practice of the present invention. Accordingly, the invention will be described below with reference to this particular vector.
  • the genetic organization of the AcNPV genome includes a strong promoter sequence associated with the polyhedrin gene.
  • the polyhedrin protein is expressed more abundantly during infection than any other protein in infected cells. High levels of foreign gene expression can be achieved in the AcNPV expression system when an exogenous gene is positioned in the vector under control of the polyhedrin promoter.
  • an exogenous gene encoding a paramyxoviral F protein is inserted into the genome of AcPNV baculoviral vector under the control of the polyhedrin promoter
  • other promoters may be employed in the expression vector, including the promoter for the lOkD protein in AcNPV or the granulin promoter in granuloais virus.
  • an exogenous gene may be inserted into the transfer vector under the control of its own promoter or a promoter constructed from synthetic oligomers.
  • the exogenous F gene may be expressed either as a nonfused protein or as a fusion protein containing a segment of amino acid residues from the polyhedrin gene.
  • Transfer vectors for producing fusion products which are known in the art include pAc401, pVLlOl, pAc436, pAc700, and the like.
  • an exogenous gene is cloned into a restriction site downstream from the polyhedrin start codon, and hence, the gene is expressed as fusion protein in which the exogenous protein is fused to several N-terminal residues of the polyhedrin protein.
  • a commonly used vector for producing non-fused proteins is pAc373; others include pAc461 and pAc610.
  • the latter type of vector is constructed by deleting different lengths of DNA upstream and downstream of the polyhedrin start codon.
  • Levels of expression of an exogenous gene can vary depending on the 5 ' proximal . leader sequence between the polyhedrin promoter and the exogenous gene. See Matsuura et al. , J. Gen. Vir., ⁇ .68.:1233-50 (1987).
  • the leader sequences in these transfer vectors contain the restriction sites utilized to insert DNA fragments into the vectors.
  • the method of the invention encompasses producing the exogenous F protein either as a fusion or non-fusion product.
  • a currently preferred transfer vector for use in expressing the exogenous F gene as a non-fused product is the transfer vector pAcYMI, which is described in Matsuura et al., J. Gen. Vir., supra. (1987)
  • the fragment containing the gene must be properly positioned relative to the polyhedrin promoter. Proper positioning of the gene for expression requires not only proper orientation of the fragment, but also placement of the fragment in the proper reading frame for expression.
  • a fusion protein is to be expressed which contains coding information for amino terminal polyhedrin residues on • I I the fusion product, the fragment must be inserted such that the exogenous gene is in phase with, and is expressed as a continuation of the polyhedrin polypeptide.
  • the transfer vector containing the exogenous gene and associated promoter is cotransfected with wild-type baculoviral DNA in a transfer host, using known methodology.
  • both the transfer host and the expression host cells are from the cultured cell line Spodoptera frugiperda
  • the recombinant virus In a transfer vector where the polyhedrin structural gene has been deleted and replaced with exogenous DNA during the recombination event, the recombinant virus will ' have lost the ability- to produce functional polyhedrin. Recombinant viruses are therefore no longer capable of forming occlusion bodies in plaques of infected cells. When the recovered virus is diluted and plated, the plaques containing recombinant virus have a visually distinguishable occ" phenotype. Further restreaking and isolation of the occ" plaques can assure attainment of a substantially pure recombinant virus 11 population.
  • the host cell for expression of the F protein may be selected from S.. f ugiperda (Sf8), Trichoplusia ni, Heliothius Zea, and Manduca sexta.
  • the polyhedrin 5 gene is known to be highly expressed in the Sf8 cell ______- ⁇ i ⁇ e. Accordingly, the exogenous F gene is placed under control of the polyhedrin promoter for expression and is expressed in Sf8 host cells.
  • Infection of the expression host cells with the 10 recombinant virus is carried out at a high multiplicity of infection.
  • Infected cells may be harvested preferably between 24 and 48 hours post infection and the recombinant fusion glycoprotein recovered from cell lysates.
  • the fusion 15 protein of human parainfluenza type 3 (PI3) virus is expressed in a form which includes a transme brane domain which secures the glycoprotein to the cell membrane. It is possible, by deleting the segment of DNA encoding the transmembrane domain of the 20 protein, to produce recombinant F protein in a form which is secreted by the host cell and released into the medium associated with the cell culture.
  • the recombinant F proteins produced in accordance with the invention are antigenically similar to their 25 naturally occurring counterparts, and are capable of inducing an immune response in host organisms.
  • Vaccines produced by the method described herein are free of any contamination by intact or infectious virus particles.
  • the recombinant F protein of the invention may be cleaved either enzymatically or chemically into immunologically important subunits for use in a vaccine. For optimum immunization against human I * . parainfluenza virus, a vaccine should contain not only
  • HN hemagglutinin-neuramidase
  • the F protein described herein may be formulated for immunization by admixture with an appropriate physiologically acceptable carrier
  • suitable carriers include, but are not limited to, water, buffered saline, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like) suitable mixtures thereof, or vegetable oils.
  • polyol for example, glycerol, propylene glycol, liquid polyethylene glycol and the like
  • suitable mixtures thereof or vegetable oils.
  • vegetable oils e.glycerol, glycerol, propylene glycol, liquid polyethylene glycol and the like
  • vegetable oils e.glycerol, glycerol, propylene glycol, liquid polyethylene glycol and the like
  • the action of contaminating microorganisms may be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. It will often be prefer
  • Modes of administration of the immunogen include oral, intranasal, intradermal, intravenous, intramuscular, intraperitioneal, subcutaneous or any other accepted route of delivery.
  • physiologically acceptable carrier includes any and all solvents, dispersion media, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like which may be appropriate for the intended mode of administration of the vaccine of the invention.
  • the use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated.
  • Supplementary active ingredients may also be incorporated into the vaccine as packaged for use, if necessary or desirable.
  • Suitable adjuvants include, but are not limited to, mineral gels, such as alum, polyanions and peptides.
  • the immunogen may also be incorporated into lipid vesicles 0 or conjugated to polysaccharides and/or other polymers suitable for use in a vaccine preparation.
  • Dosage unit form as used 5 herein refers to a physically discrete unit of vaccine appropriate for the host to be immunized. Each dosage should contain the quantity of active material calculated to produce the desired therapeutic effect in association with the selected pharmaceutical carrier. 20.. Procedures for determining the appropriate vaccine dosage for a given class of host are well known to those skilled in art. Generally, when administering a composition comprising the HN and F antigens of the virus, a dosage of about 10-200 .g should be 25 satisfactory for producing the desired immune response.
  • Viruses of the paramyxovirus group are responsible for causing infections in a wide variety of vertebrate hosts, including, e.g., humans, cattle and birds.
  • the 30 above-described vaccine formulations are suitable for administration to any vertebrate host which is susceptible to such infections.
  • the preferred vaccines of the invention, intended for prevention of parainfluenza infection are most valuable in treatment of mammalian hosts, including man.
  • the recombinant F protein of human parainfluenza type 3 (PI3) virus described in this example was produced in Sf8 cells using the transfer vector pAcYMI. a. Virus and cells
  • Human PI3 virus (strain 47885) was obtained from the National Institute of Allergy and Infectious Disease (Bethesda, MD) . African green monkey kidney (LLC-MK2), baby hamster kidney (BHK) and Vero cells were obtained from the American Type culture Collection (Rockville, MD) . LLC-MK2 cells were used for PI3 vi ⁇ us growth as previously described. Ray et al., J. Inf. Dis., supra. , (1985). BHK cells were used for fusion inhibition assays, and Vero cells were used for plaque assays and virus neutralization tests. Ray et al., J. Gen. Vir., _68_:409-18 (1987).
  • the plasmid DNA was isolated, digested with Bam HI and analyzed by agarose gel electrophoresis. The F-gene fragment, of approximately 1900 base pairs, was eluted from an agarose gel and subcloned into the baculovirus transfer vector pAcYMI. The plasmid pAcYMI was digested with Bam HI, dephosphorylated with calf intestinal alkaline phosphatase, ligated to the eluted F fragment, and used to transform E coli.
  • a 200 base pair Bgl II restriction fragment from the F gene was isolated by electrophoresis in a 1% low raetling agarose gel.
  • the restriction fragment was excised, dissolved in distilled water, radiolabeled with 32pdCTP by a random primed oligonucleotide labelling method using a kit from Pharmacia (Pharmacia, New Jersey) . This probe was used for dot blot, slot blot and Southern blot analyses. d. Transfection and Selection
  • Sf8 cells were infected with 0.1 pfu/cell of wild type AcNPV and grown in TC-100 medium containing 10% fetal bovine serum for 48 h at 27°C.
  • Virus was harvested from culture fluid, purified by centrifugation through a 25-56%. linear sucrose gradient and the DNA isolated by treatment with proteinase K and sarkosyl following the methodology of Summers and Smith, A Manual of Methods for Baculovirus Vectors and ⁇
  • pAcYMI-PI3F plasmid DNA was prepared from transformed bacterial cells by two cycles of CsCl gradient centrifugation and ethanol precipitation. Sf8 cells were transfected with mixtures of DNA from AcNPV and PACYMI-PI3F plasmid DNA following the methodology of Matsuura et al., J. Gen. Vir., supra. (1987).
  • DNA from AcNPV was mixed with different concentrations of plasmid DNA (10 to 50 ⁇ g) and adjusted to 950 ⁇ . ⁇ 1 with HEPES-buffered saline (20 mM HEPES, 1 mM a 2 HP04, 5 nM KCl, 140 nM NaCl, 10 M glucose, pH 7.05). After precipitation with 50 ⁇ .1 of 2.5 M CaCl2, DNA was added on 2 x 10 6 Sf8 cells grown in 60 mm tissue culture dishes and incubated for 1 h at 27°C. The supernatant fluid was discarded and 3 ml of TC-100 containing heat inactivated 10% fetal bovine serum was added in each dish and incubated for 4-5 days at 27°C.
  • the culture fluid from each dish was seria.lly diluted ten fold and inoculated into Sf8 cells for * plaque assay as described by Summers and Smith, supra. Plaques showing absence of polyhedra were screened by a phase contrast microscope and transferred to a 100 well tissue culture plate containing Sf8 cells and incubated at 27°C for 48 h. e. Isolation of Recombinant Virus
  • Putative recombinant viruses isolated at each step of plaque purification were screened by dot or slot blot hybridization using the 32 P-labeled restriction enzyme fragment of the F-cDNA, described in step (c), above. See: Kafatos et al., Nucl. Acids Res., :1541 (1979). Positive viruses were successively plaque purified until microscopic observation. following 5-7 days of incubation, showed an absence of polyhedra. plaque purified recombinant virus was grown in 100 mm cell culture dishes with an average yield of 10 7 pfu/ml.
  • Total DNA from uninfected, AcNPV infected, and recombinant baculovirus infected Sf8 cells at 24-48 h post infection were prepared as described by Summers and Smith, supra, for Southern blot analysis. DNA preparations were digested with Bam HI, phenol extracted, and precipitated with ethanol. Electrophoresis was done in 1% agarose gels and transferred onto nitrocellulose membrane. The membrane was baked at 80°C for 2 h and hybridized with 32 P-labeled F-gene probe in 50% formamide, 5 x SSC, 1 x Denhardt's solution, 0.2 M sodium phosphate and 0.2% SSC at 37°C for 24 h.
  • recombinant virus clones pACYMl-PI3F exhibited a band around 1900 base pair which corresponded to the calculated size of the inserted F gene.
  • the additional minor band of slow electrophoretic mobility, also shwn in Fig. 2 is probably due to incomplete digestion of the inserted DNA by the restriction enzyme.
  • Recombinant baculovirus Sf8 cells were analyzed for production of the F protein by immune precipitation with specific monoclonal antibody or monospecific rabbit antibody to the affinity purified F protein of the virus, both as previously described. See: Ray et al., J. Infect. Dis., supra. (1985) and Ray et al. , J. Gen. Virol., supra., respectively. Cells were radiolabeled with 35 S-methionine in methionine free ⁇ ⁇ • l
  • TC-100 medium at 27°C for 1 h.
  • Cell lysis and processing for immune precipitation were carried out as previously described. See: Ray et al . , J. Gen. Virol., supra. , (1987).
  • Immune precipitates were analyzed, as shown in Fig. 3, by 7.5% SDS-PAGE under non-reducing (lanes 1 to 4) or reducing conditions (lanes 5 to 8) .
  • the numbers shown on the right of Fig. 3 represent the positions of molecular weight markers in kilodaltons. As can be seen in Fig. 3, two closely migrating polypeptide bands around 70 kilodaltons were precipitated from the recombinant virus infected Sf8 cell lysate when t run under non-reducing conditions.
  • the two bands may reflect differences in glycosylation of the fusion protein.
  • the recombinantly produced protein comigrated with the authentic viral protein obtained from PI3 virus-infected LLC-MK2 cell lysate using*similar experimental conditions. Unlike the F protein from PI3 virus infected cells, in which the F protein is dissociated into FT. and F2 subunits, no difference in electrophoretic mobility for the recombinant F protein was observed using reducing conditions. This suggests that the Sf8 cells may not be capable of proteolytic cleavage of the expressed F protein under these experimental conditions.
  • Uninfected Sf8 cells or recombinant virus infected cells were harvested from thirty 100 mm dishes and washed twice with PBS, pH 7.2. Cell pellets were suspended in 0.1 M Tris, HCl, 0.1 M NaCl, pH 7.6 containing 2% n-octyl- ⁇ -D-glucopyranoside and incubated at room temperature for 60 minutes. The cell suspension was centrifuged at 300,000 X g for 30 minutes. The clear supernatant was collected, dialyzed against 0.01 M Tris-HCl and 0.01 M NaCl, pH 7.6 for 72 h at 4°C and concentrated to about 1.5 ml volume. Detergent solubilized proteins from uninfected or recombinant virus infected cells were mixed with Freund's complete adjuvant for immunization of test animals.
  • Example 2 The protective response to administration of the F protein, formulated as a vaccine, was compared to that achieved by administration of affinity purified fusion protein from live PI3 virus.
  • F protein prepared as described in Example 1, above was injected intramuscularly into the hind legs of hamsters, which were further subcutaneously immunized with similar quantities of F protein for two subsequent weeks.
  • purified PI3 virus was suspended in distilled water, freeze-dried and used for similar immunization of a positive control group of hamsters for comparison.
  • Sera of the test animals were prepared by bleeding from the retro-orbital plexus on the tenth day after the last immunization for determination of antibody response against the expressed PI3 fusion protein.
  • Sera were tested against affinity purified F protein of PI3 by ELISA as described in Ray et al.. J. Inf. Pis., 157:648 (1988) for virus neutralization, and for fusion inhibition activities as previously described. See: Ray et al . , J. Gen. Virol., supra.
  • the antibody response and its protective role are summarized in Table I.
  • Antisera to the detergent soluble cell surface proteins were analyzed for specificity against affinity purified F protein of PI3 virus by ELISA.
  • Immunoglobulin (Ig) portions from hamster sera were prepared by 50% (NH4)2S ⁇ 4 precipitation and tested for fusion inhibition activity on PI3 infected BHK cells.
  • Ig from hamsters immunized with recombinant baculovirus infected cellular proteins demonstrated fusion inhibition activity up to a dilution of 1:20. Similar fusion inhibition activity up to a dilution of 1:80 was observed with Ig from animals immunized with untreated whole PI3 virus (group III). However, Ig from control animals (group I) did not show any detectable fusion inhibition activity. Antisera to the F protein of the invention also showed significant virus neutralizing activity as compared with the sera from a control group of animals.
  • mice were challenged by intranasal infection with live PI3 virus four weeks after the last immunization.
  • the hamsters were anesthetized and lOO ⁇ u-l of virus suspension was instilled in both the nostrils.
  • the animals were sacrificed 3 days post infection.
  • Virus titers in 11 lungs and trachea ho ogenate were determined by plaque assay on Vero cell onolayers as previously described. Ray et al., J. Inf. Dis., supra. , (1985). Animals previously immunized with recombinant F protein demonstrated about seven fold reduction in virus titer in their lungs and trachea homogenate as compared to the control group of animals.
  • a protein having the properties of the F protein of human PI3 virus may be successfully expressed using a baculovirus expression system.
  • the resultant protein shows reactivity with specific monoclonal and polyclonal antibodies to the F glycoprotein of PI3 virus and comigrates with the authentic F glycoprotein, although the protein does not appear to be proteolytically cleaved to F and F2 subunits as the position of the expressed protein remains unaltered following electrophoresis under reducing conditions.
  • Antigenic activity of the expressed F protein appears to be retained, since antisera raised against it demonstrates virus neutralization activity and fusion inhibition activity. Additionally, immunized test animals showed approximately seven fold reduction in virus titer following challenge infection compared with a negative control group.
  • proteins having the properties of the F proteins of other viruses of the paramyxoviruses 13 group may be produced following the same general procedure.
  • higher yields of the protein of the invention may be obtainable by deletion of the 5 1 non-coding end region from the F gene and deletion of the nucleotides encoding the transmembrane anchoring sequences. The latter deletion will allow secretion of the recombinant F protein into the culture medium from which it may be readily recovered.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

On produit une protéine présentant l'activité antigénique d'une protéine de fusion paramyxovirale (protéine F), à l'aide d'une technologie d'ADN de recombinaison dans des cellules d'insectes infectées par un vecteur d'expression de baculovirus. L'immunisation des sujets du test à l'aide de la protéine de l'invention est à l'origine d'anticorps ayant neutralisé l'infectiosité et bloqué la fusion de cellules infectées par le virus.
PCT/US1989/003740 1988-09-02 1989-08-29 Proteine de fusion de paramyxovirus, procede de production utilisant un vecteur d'expression de baculovirus de recombinaison, vaccin comprenant ladite proteine et son utilisation WO1990002566A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK91375A DK37591D0 (da) 1988-09-02 1991-03-01 Fusionsprotein fra paramyxovirus, fremgangsmaade til fremstilling deraf under anvendelse af rekombinant baculovirus-ekspressionsvektor, vaccine indeholdende proteinet samt dets anvendelse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24087788A 1988-09-02 1988-09-02
US240,877 1988-09-02

Publications (1)

Publication Number Publication Date
WO1990002566A1 true WO1990002566A1 (fr) 1990-03-22

Family

ID=22908302

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/003740 WO1990002566A1 (fr) 1988-09-02 1989-08-29 Proteine de fusion de paramyxovirus, procede de production utilisant un vecteur d'expression de baculovirus de recombinaison, vaccin comprenant ladite proteine et son utilisation

Country Status (8)

Country Link
EP (1) EP0433371A4 (fr)
JP (1) JPH04501058A (fr)
AU (1) AU4314489A (fr)
DK (1) DK37591D0 (fr)
IL (1) IL91500A0 (fr)
NZ (1) NZ230425A (fr)
WO (1) WO1990002566A1 (fr)
ZA (1) ZA896715B (fr)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169628A (en) * 1988-04-22 1992-12-08 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
WO1993001833A1 (fr) * 1991-07-17 1993-02-04 Commonwealth Scientific And Industrial Research Organisation Vaccin ameliore
US5298239A (en) * 1991-10-07 1994-03-29 The Research Foundation Of State University Of New York Mutations rendering platelet glycoprotein IB α less reactive
US5317097A (en) * 1991-10-07 1994-05-31 The Research Foundation Of State University Of New York Mutations in the gene encoding the α chain on platelet glycoprotein IB
WO1995024214A1 (fr) * 1994-03-07 1995-09-14 Bayer Aktiengesellschaft Vaccins contre le syndrome respiratoire reproductif porcin, renfermant des virus para-influenza
US5554526A (en) * 1990-11-29 1996-09-10 Fujikura Kasei Co., Ltd. Human parainfluenza virus type 4A fusion protein and gene coding for the same
US5641751A (en) * 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
WO2006069246A2 (fr) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
WO2008030558A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
WO2009067636A2 (fr) 2007-11-20 2009-05-28 Ambrx, Inc. Polypeptides d'insuline modifiés et leurs utilisations
WO2010011735A2 (fr) 2008-07-23 2010-01-28 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
WO2010037062A1 (fr) 2008-09-26 2010-04-01 Ambrx, Inc. Vaccins et micro-organismes dépendant de la réplication d'acide aminé non naturels
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
EP2284191A2 (fr) 2004-12-22 2011-02-16 Ambrx, Inc. Procédé de préparation de hGH
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
EP2327724A2 (fr) 2004-02-02 2011-06-01 Ambrx, Inc. Polypeptides d'hormone de croissance humaine et leur utilisations
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2012024452A2 (fr) 2010-08-17 2012-02-23 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
EP2805965A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
EP2805964A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP3103880A1 (fr) 2008-02-08 2016-12-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
US12138296B2 (en) 2022-02-02 2024-11-12 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743553A (en) * 1984-07-18 1988-05-10 W. R. Grace & Co. Synthetic genes for bovine parainfluenza virus
US4847081A (en) * 1984-07-18 1989-07-11 W. R. Grace & Co.-Conn. Synthetic bovine parainfluenza viral proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6226300A (ja) * 1984-10-10 1987-02-04 セントコ−・インコ−ポレ−テツド Ｈｔｌｖ−３ｄｎａのクロ−ニングおよび発現

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743553A (en) * 1984-07-18 1988-05-10 W. R. Grace & Co. Synthetic genes for bovine parainfluenza virus
US4847081A (en) * 1984-07-18 1989-07-11 W. R. Grace & Co.-Conn. Synthetic bovine parainfluenza viral proteins

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Journal of General Virology, Volume 68, issued 1987, Y. MATSUURA, pages 1235-1250. *
Journal of Virology, Volume 61, Number 6, issued June 1987, R.G. PATERSON, pages 1972-1977. *
Journal of Virology, Volume 62, Number 4, issued April 1988, M.K. SPRIGGS, pages 1293-1296. *
The Journal of Infectious Diseases, Volume 152, Number 6, issued December 1985, R. RAY, pages 1219-1230. *
The Journal of Infectious Diseases, Volume 155, Number 6, issued June 1987, E. E. WASH, pages 1198-1204. *
The Journal of Infectious Diseases, Volume 157, Number 4, issued April 1988, K.L. VAN WYKE COELINGH, pages 655-662. *
Virology, Volume 143, issued 1985, K.L. VAN WYKE COELINGH, pages 569-582 *
Virology, Volume 160, issued 1987, K.L. VAN WYKE COELINGH, pages 465-472. *

Cited By (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169628A (en) * 1988-04-22 1992-12-08 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
US5554526A (en) * 1990-11-29 1996-09-10 Fujikura Kasei Co., Ltd. Human parainfluenza virus type 4A fusion protein and gene coding for the same
WO1993001833A1 (fr) * 1991-07-17 1993-02-04 Commonwealth Scientific And Industrial Research Organisation Vaccin ameliore
US5298239A (en) * 1991-10-07 1994-03-29 The Research Foundation Of State University Of New York Mutations rendering platelet glycoprotein IB α less reactive
US5317097A (en) * 1991-10-07 1994-05-31 The Research Foundation Of State University Of New York Mutations in the gene encoding the α chain on platelet glycoprotein IB
US5910310A (en) * 1994-03-07 1999-06-08 Bayer Aktiengesellschaft Porcine parainfluenza virus type 2
AU700160B2 (en) * 1994-03-07 1998-12-24 Bayer Aktiengesellschaft Vaccine containing parainfluenza viruses for the prevention of respiratory and reproductive diseases of the pig
WO1995024214A1 (fr) * 1994-03-07 1995-09-14 Bayer Aktiengesellschaft Vaccins contre le syndrome respiratoire reproductif porcin, renfermant des virus para-influenza
US5641751A (en) * 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
EP2327724A2 (fr) 2004-02-02 2011-06-01 Ambrx, Inc. Polypeptides d'hormone de croissance humaine et leur utilisations
US9260472B2 (en) 2004-02-02 2016-02-16 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8907064B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8232371B2 (en) 2004-02-02 2012-07-31 Ambrx, Inc. Modified human interferon polypeptides and their uses
US8097702B2 (en) 2004-02-02 2012-01-17 Ambrx, Inc. Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
US8178108B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US7829310B2 (en) 2004-12-22 2010-11-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7846689B2 (en) 2004-12-22 2010-12-07 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7858344B2 (en) 2004-12-22 2010-12-28 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7883866B2 (en) 2004-12-22 2011-02-08 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
EP2284191A2 (fr) 2004-12-22 2011-02-16 Ambrx, Inc. Procédé de préparation de hGH
WO2006069246A2 (fr) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
US8143216B2 (en) 2004-12-22 2012-03-27 Ambrx, Inc. Modified human growth hormone
US7959926B2 (en) 2004-12-22 2011-06-14 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone mutants
US8163695B2 (en) 2004-12-22 2012-04-24 Ambrx Formulations of human growth hormone comprising a non-naturally encoded amino acid
US7838265B2 (en) 2004-12-22 2010-11-23 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
EP2399893A2 (fr) 2004-12-22 2011-12-28 Ambrx, Inc. Compositions contenant des acides aminés et des polypeptides non naturels, procédés les impliquant et leurs utilisations
US8178494B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Modified human growth hormone formulations with an increased serum half-life
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US8618257B2 (en) 2006-09-08 2013-12-31 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
US7919591B2 (en) 2006-09-08 2011-04-05 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US8053560B2 (en) 2006-09-08 2011-11-08 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
WO2008030558A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
US8022186B2 (en) 2006-09-08 2011-09-20 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US10961291B2 (en) 2007-03-30 2021-03-30 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8383365B2 (en) 2007-03-30 2013-02-26 Ambrx, Inc. Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
US10377805B2 (en) 2007-03-30 2019-08-13 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
US9517273B2 (en) 2007-03-30 2016-12-13 Ambrx, Inc. Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US11993637B2 (en) 2007-03-30 2024-05-28 Ambrx, Inc. Modified FGF-21 polypeptides with non-naturally encoded amino acids
US9079971B2 (en) 2007-03-30 2015-07-14 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US9975936B2 (en) 2007-03-30 2018-05-22 Ambrx, Inc. Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2009067636A2 (fr) 2007-11-20 2009-05-28 Ambrx, Inc. Polypeptides d'insuline modifiés et leurs utilisations
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2930182A1 (fr) 2007-11-20 2015-10-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP3103880A1 (fr) 2008-02-08 2016-12-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
EP3225248A1 (fr) 2008-07-23 2017-10-04 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
WO2010011735A2 (fr) 2008-07-23 2010-01-28 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
WO2010037062A1 (fr) 2008-09-26 2010-04-01 Ambrx, Inc. Vaccins et micro-organismes dépendant de la réplication d'acide aminé non naturels
US10428333B2 (en) 2008-09-26 2019-10-01 Ambrx Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US9644014B2 (en) 2008-09-26 2017-05-09 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
EP3216800A1 (fr) 2008-09-26 2017-09-13 Ambrx, Inc. Polypeptides d'érythropoïétine animale modifiés et leurs utilisations
US9121025B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US9156899B2 (en) 2008-09-26 2015-10-13 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
EP2805965A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
EP2805964A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
US8735539B2 (en) 2010-08-17 2014-05-27 Ambrx, Inc. Relaxin polypeptides comprising non-naturally encoded amino acids
US9962450B2 (en) 2010-08-17 2018-05-08 Ambrx, Inc. Method of treating heart failure with modified relaxin polypeptides
EP4302783A2 (fr) 2010-08-17 2024-01-10 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US11786578B2 (en) 2010-08-17 2023-10-17 Ambrx, Inc. Modified relaxin polypeptides and their uses
US10253083B2 (en) 2010-08-17 2019-04-09 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US11439710B2 (en) 2010-08-17 2022-09-13 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
WO2012024452A2 (fr) 2010-08-17 2012-02-23 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US11311605B2 (en) 2010-08-17 2022-04-26 Ambrx, Inc. Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US10702588B2 (en) 2010-08-17 2020-07-07 Ambrx, Inc. Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
US10751391B2 (en) 2010-08-17 2020-08-25 Ambrx, Inc. Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
US9452222B2 (en) 2010-08-17 2016-09-27 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
US11248031B2 (en) 2014-10-24 2022-02-15 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US10377806B2 (en) 2014-10-24 2019-08-13 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
US10189883B2 (en) 2014-10-24 2019-01-29 Bristol-Myers Squibb Company Therapeutic uses of modified FGF-21 polypeptides
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US11185570B2 (en) 2017-02-08 2021-11-30 Bristol-Myers Squibb Company Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US11364281B2 (en) 2017-02-08 2022-06-21 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US12097241B2 (en) 2017-02-08 2024-09-24 Bristol-Myers Squibb Company Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides
US12097242B2 (en) 2017-02-08 2024-09-24 Bristol-Myers Squibb Company Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides
US12138296B2 (en) 2022-02-02 2024-11-12 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof

Also Published As

Publication number Publication date
ZA896715B (en) 1990-09-26
NZ230425A (en) 1992-07-28
AU4314489A (en) 1990-04-02
EP0433371A1 (fr) 1991-06-26
DK37591A (da) 1991-03-01
EP0433371A4 (en) 1991-10-30
DK37591D0 (da) 1991-03-01
IL91500A0 (en) 1990-04-29
JPH04501058A (ja) 1992-02-27

Similar Documents

Publication Publication Date Title
WO1990002566A1 (fr) Proteine de fusion de paramyxovirus, procede de production utilisant un vecteur d'expression de baculovirus de recombinaison, vaccin comprenant ladite proteine et son utilisation
US5505941A (en) Recombinant avipox virus and method to induce an immune response
US5174993A (en) Recombinant avipox virus and immunological use thereof
AU690210B2 (en) Recombinant virus
FI102382B (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykopro teiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoprotei ineja varten
EP2073839B1 (fr) Vaccin contre l'infection par le virus chikungunya
Plana-Duran et al. Oral immunization of rabbits with VP60 particles confers protection against rabbit hemorrhagic disease
Marín et al. Immunogenic properties of rabbit haemorrhagic disease virus structural protein VP60 expressed by a recombinant baculovirus: an efficient vaccine
Ray et al. Expression of the fusion glycoprotein of human parainfluenza type 3 virus in insect cells by a recombinant baculovirus and analysis of its immunogenic property
EP0538341B1 (fr) Vaccin a base de glycoproteine de vhe-4 (virus d'herpes equin-4)
EP0704528B1 (fr) Virus de l'hémorragie des lapins (RHDV), capsides recombinants, protéines, et trousse de diagnostic et vaccins les contenant
WO2024008014A1 (fr) Composition pharmaceutique pour résister à une infection par le sars-cov-2 ou un mutant de celui-ci et médicament combiné associé
AU654186B2 (en) Recombinant vaccine against Marek's disease
JPH07236489A (ja) ウマヘルペスウイルス感染からウマを防御するためのワクチン
EP0668355A1 (fr) Vaccin pour protéger des chevaux contre des infections du virus de l'herpes équin
WO1989000196A1 (fr) Proteines virales presentant une glycosylation a liaison o reduite
US5674735A (en) DNA encoding the EHV-4 gH or gC glycoprotein
JP2759036B2 (ja) 単純ヘルペスウイルス感染に対するワクチン
AU672870B2 (en) Vaccines against varicella-zoster virus (VZV)
AU761321B2 (en) Recombinant viruses, vaccines containing them and in vitro cell cultures thereof
MXPA01010481A (es) Acidos nucleicos y polipeptidos de lisavirus quimerico.
JPH03504082A (ja) 昆虫細胞によるプラスモディウム属サーカムスポロゾイト蛋白の発現
AU725985B2 (en) Recombinant virus
WO2024073766A2 (fr) Vaccin sous-unitaire sûr, compatible avec diva contre virus de la peste porcine africaine
IE60309B1 (en) Recombinant viruses, vaccines containing them and in vitro cell cultures thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989910526

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989910526

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989910526

Country of ref document: EP